SCHEDULE: KalVista Pharma Ownership Update Filed

KalVista Pharmaceuticals, Inc. has filed an amendment to its Schedule 13G, reporting on beneficial ownership as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G for KalVista Pharmaceuticals, Inc.
• It reports on the beneficial ownership of common stock as of June 30, 2026.
• The filing lists several reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh.
• All reporting entities were organized in Delaware, while Nimish Shah and Bong Koh are U.S. citizens.
• The filing indicates that the reporting persons are members of a group for the purposes of this Schedule 13G/A.
• Crucially, all reporting persons state they beneficially own 0.00 shares and represent 0.0% of the class of securities.
• The filing includes certifications that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update with no new material information regarding ownership changes or strategic shifts.

Positives

• The filing confirms that the reporting persons hold 0% of the company's shares, indicating no significant new stake or change in control intentions.
• The administrative nature of the filing suggests no immediate disruptive events related to these specific reporting entities.

Negatives

• The filing does not provide any new financial performance data or strategic updates for KalVista Pharmaceuticals, Inc.

Risks

• The filing does not explicitly mention any new risks or challenges.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically used by institutional investors to report passive ownership stakes. The absence of any reported beneficial ownership by these entities suggests a change from any previous holdings or a confirmation of a non-controlling interest, which is common in the biotechnology sector where significant capital is often required for development.

Stakeholder Impact

• Shareholders: The filing confirms a lack of significant beneficial ownership by the named reporting persons, which may be interpreted as a lack of immediate intent to influence control or acquire a substantial stake.

Key Dates

Keywords

KalVista Pharmaceuticals, Schedule 13G, Beneficial Ownership, Venrock Healthcare Capital Partners, Securities Exchange Act, Ownership Update